How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,506 results for

First Generation Sulfonylurea

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1481. Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin)

). Please remove one or more studies before adding more. Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00708578 Recruitment Status : Completed First Posted : July 2, 2008 Last Update Posted (...) . For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Type 2 diabetes for at least 6 months Treated with maximal, tolerable dose of metformin (≥ 1000mg/day) and sulfonylurea (glimepiride≥ 4 mg/day or equivalent dose of other SU) for at least 3 months prior to the screening visit 7.0 < HbA1c < 11 % Fasting serum C-peptide > 0.33 nmol/L BMI

2008 Clinical Trials

1482. Sulfonylurea Effects on Glucagon Regulation During Hypoglycemia in Type 1 DM

. Sulfonylurea Effects on Glucagon Regulation During Hypoglycemia in Type 1 DM The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00515801 Recruitment Status : Completed First Posted : August 14, 2007 Last Update Posted : March 9, 2012 Sponsor: University Hospital, Basel, Switzerland Information provided (...) , Switzerland More Information Go to Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Layout table for additonal information Responsible Party: University Hospital, Basel, Switzerland ClinicalTrials.gov Identifier: Other Study ID Numbers: EKBB 57/07 SB First Posted: August 14, 2007 Last Update Posted: March 9, 2012 Last Verified: March 2012 Keywords provided by University Hospital, Basel, Switzerland: diabetes mellitus type 1 hypoglycemia sulfonylurea glucagon

2007 Clinical Trials

1483. A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas

of saved studies (100). Please remove one or more studies before adding more. A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00313313 Recruitment Status : Completed First Posted : April 12 (...) , 2006 Results First Posted : September 25, 2009 Last Update Posted : May 4, 2015 Sponsor: AstraZeneca Information provided by (Responsible Party): AstraZeneca Study Details Study Description Go to Brief Summary: The purpose of this trial is to understand if adding saxagliptin to a sulfonylurea is safe and works better than increasing the amount of sulfonylurea a patient takes Condition or disease Intervention/treatment Phase Diabetes Drug: Saxagliptin Drug: Glyburide Drug: Placebo Drug: Metformin

2006 Clinical Trials

1484. Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.

this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 80 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Type 2 diabetes HbA1C: At least 8% Patients that were never treated with insulin before Current therapy with metformin and a sulfonylurea. Exclusion Criteria: History of recurrent (...) Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea. Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved

2006 Clinical Trials

1485. Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes

of saved studies (100). Please remove one or more studies before adding more. Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00395746 Recruitment Status : Completed First Posted (...) decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 20 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Type 2 diabetes Diet/exercise therapy with sulfonylurea (SU

2006 Clinical Trials

1486. Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy

of saved studies (100). Please remove one or more studies before adding more. Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00358124 Recruitment Status : Completed First Posted : July (...) Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2006 Clinical Trials

1487. Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin

studies (100). Please remove one or more studies before adding more. Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00324363 Recruitment Status : Completed First Posted : May 11, 2006 Last (...) Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2006 Clinical Trials

1488. The Beta Cell Responsiveness to Glucose-dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 Diabetes

University Hospital ClinicalTrials.gov Identifier: Other Study ID Numbers: KA-05011 First Posted: May 3, 2006 Results First Posted: October 2, 2008 Last Update Posted: July 16, 2015 Last Verified: September 2008 Keywords provided by University Hospital, Gentofte, Copenhagen: Type 2 diabetes mellitus Glucose dependent insulinotropic polypeptide Sulfonylurea compounds insulin secretion Sulfonylurea receptor subunit-SUR1 Impaired incretin effect Additional relevant MeSH terms: Layout table for MeSH terms (...) The Beta Cell Responsiveness to Glucose-dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 Diabetes The Beta Cell Responsiveness to Glucose-dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 Diabetes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

2006 Clinical Trials

1489. Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea

Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00327626 Recruitment Status : Withdrawn (study

2006 Clinical Trials

1490. Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea

of saved studies (100). Please remove one or more studies before adding more. Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00455598 Recruitment Status : Completed First Posted : April 3 (...) of subjects with type 2 diabetes are obese and have lipid abnormalities, these additional potential properties of ISIS 113715 make it an attractive potential therapeutic for type 2 diabetes. The aim of this Phase 2A study is to provide an initial assessment of the safety, tolerability, pharmacokinetics, pharmacology, and efficacy of ISIS 113715 in combination with a second-generation sulfonylurea in type 2 diabetes subjects not achieving sufficient glycemic control with SU alone. Study Design Go to Layout

2007 Clinical Trials

1491. Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin

Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study (...) Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier

2006 Clinical Trials

1492. Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control

Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control The safety and scientific validity of this study

2006 Clinical Trials

1493. Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes

number of saved studies (100). Please remove one or more studies before adding more. Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00367055 Recruitment Status : Completed First (...) Posted : August 22, 2006 Results First Posted : November 5, 2009 Last Update Posted : July 27, 2010 Sponsor: GlaxoSmithKline Information provided by: GlaxoSmithKline Study Details Study Description Go to Brief Summary: It has been shown in previous study that progressive glycemic deterioration was associated with progressive loss of b-cell function, measured by the decrease in plasma insulin levels, irrespective of the therapy used (diet, sulfonylureas or metformin).There is growing evidence

2006 Clinical Trials

1494. Sulfonylurea Response in Patients With Diabetes Due to Kir6.2 Mutations

, UK More Information Go to Additional Information: Publications of Results: Other Publications: Layout table for additonal information ClinicalTrials.gov Identifier: Other Study ID Numbers: 2003/10/196 97/29/AH/mbs NTNU Jnr 207/mkd NTNU CCPPRB Necker GLIDKIR6.2 First Posted: June 8, 2006 Last Update Posted: November 29, 2006 Last Verified: June 2006 Keywords provided by Royal Devon and Exeter NHS Foundation Trust: Permanent Neonatal Diabetes Kir6.2 KCNJ11 Infancy onset diabetes Sulfonylurea (...) Sulfonylurea Response in Patients With Diabetes Due to Kir6.2 Mutations Sulfonylurea Response in Patients With Diabetes Due to Kir6.2 Mutations - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Sulfonylurea

2006 Clinical Trials

1495. Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.

studies before adding more. Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00286468 Recruitment Status : Completed First Posted : February 3, 2006 Results First Posted : August 25, 2011 Last Update Posted (...) Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus. Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2006 Clinical Trials

1496. Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin

of saved studies (100). Please remove one or more studies before adding more. Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00269061 Recruitment Status : Completed First Posted (...) Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2005 Clinical Trials

1497. A Study of the Efficacy and Safety of Topiramate in Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy

for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Diagnosis of Type 2 Diabetes, receiving only second generation sulfonylurea therapy (may include: glipizide, gliclazide, glimepiride, glibenclamide/glyburide, and gliquadone) for at least 4 months and on stable dose for at least 2 months Body Mass Index >= 27 and < 50 HbA1c < 11% at enrollment Diagnosed hypertension or hyperlipidemia must be controlled Female patients must be postmenopausal for at least 1 year, surgically (...) Pharmaceutical Research & Development, L.L.C. More Information Go to Additional Information: Layout table for additonal information ClinicalTrials.gov Identifier: Other Study ID Numbers: CR002251 First Posted: October 4, 2005 Last Update Posted: June 8, 2011 Last Verified: January 2011 Keywords provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.: Obesity Type 2 Diabetes Mellitus HbA1c Sulfonylurea Topiramate Adult-Onset Diabetes Mellitus (AODM) Additional relevant MeSH terms: Layout

2005 Clinical Trials

1498. WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes

and Sulfonylurea in Treating Patients With Type 2 Diabetes The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00147758 Recruitment Status : Completed First Posted : September 7, 2005 Last Update Posted : January 18, 2012 Sponsor: Daiichi Sankyo, Inc. Information provided by (Responsible Party): Daiichi Sankyo, Inc (...) provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Age 18-75 years, inclusive Diagnosed with type 2 diabetes Stable dose of sulfonylurea alone or in combination with other anti-diabetic medications for 90 days Hemoglobin A1c value 7.5% to 9.5%, inclusive C peptide > 0.5 ng/mL Prescribed ADA diet Exclusion Criteria

2005 Clinical Trials

1499. CARDIAC SULFONYLUREA RECEPTOR SHORT FORM-BASED CHANNELS CONFER A GLIBENCLAMIDE-INSENSITIVE KATP ACTIVITY (Full text)

CARDIAC SULFONYLUREA RECEPTOR SHORT FORM-BASED CHANNELS CONFER A GLIBENCLAMIDE-INSENSITIVE KATP ACTIVITY The cardiac sarcolemmal ATP-sensitive potassium channel (K(ATP)) consists of a Kir6.2 pore and an SUR2 regulatory subunit, which is an ATP-binding cassette (ABC) transporter. K(ATP) channels have been proposed to play protective roles during ischemic preconditioning. An SUR2 mutant mouse was previously generated by disrupting the first nucleotide-binding domain (NBD1), where a glibenclamide

2007 Journal of Molecular and Cellular Cardiology PubMed abstract

1500. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. (Full text)

category. Disease severity indicators were identified among the administrative data and entered as covariates in each model. The main outcomes were all-cause mortality and death from an acute ischemic event.The mean age of the cohort members was 66.3 (standard deviation [SD] 13.4) years; 43.4% were female; and their mean duration of follow-up was 4.6 (SD 2.1) years. First-generation sulfonylureas were used exclusively by 120 subjects; glyburide, by 4138; and metformin, by 1537. A greater risk of death (...) was associated with higher daily doses of the first-generation sulfonylureas (adjusted hazard ratio [HR] 2.1, 95% confidence interval [CI] 1.0-4.7) and glyburide (HR 1.3, 95% CI 1.2-1.4), but not metformin (HR 0.8, 95% CI 0.7-1.1). Similar associations were observed for death caused by an acute ischemic event.Higher exposure to sulfonylureas was associated with increased mortality among patients newly treated for type 2 diabetes. The same relation was not observed with metformin. This implies that the manner

2006 Canadian Medical Association Journal PubMed abstract

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>